BIOKEYS PRESS RELEASE

Seite 1 von 1
neuester Beitrag: 13.06.01 12:22
eröffnet am: 13.06.01 11:22 von: DonHappy Anzahl Beiträge: 2
neuester Beitrag: 13.06.01 12:22 von: DonHappy Leser gesamt: 157
davon Heute: 1
bewertet mit 0 Sternen

13.06.01 11:22

549 Postings, 7423 Tage DonHappyBIOKEYS PRESS RELEASE

hier - wie bereits angekündigt - Press Release Nr. 1:

Biokeys Pharmaceuticals, Inc. Announces Expanded Patent and Technology
License Agreement with The University of Texas M. D. Anderson Cancer
Center

SAN DIEGO--(BW HealthWire)--June 12, 2001--Biokeys Pharmaceuticals, Inc. (Pink Sheets: BKYS) announced today that it
has entered into an expanded Patent and Technology License Agreement with The University of Texas M. D. Anderson
Cancer Center. The agreement modifies the consideration granted M. D. Anderson for the license, grants important
additional licensed subject matter in the area of HIV vaccine, and grants the Company right of first refusal for additional
technologies.

Under the terms of the agreement, M. D. Anderson has (1) taken a position of 414,830 common shares of the Company, (2)
substantially reduced the royalty rate paid by the Company to M. D. Anderson on eventual sales of the Company's products
developed using the licensed subject matter, (3) granted rights to additional patents and patent applications pertaining to
licensed subject matter specifically in the field of cell mediated immunity inducing HIV vaccine, and (4) given a right of first
refusal to license any technology developed by the scientists and labs covered in the original Patent and Technology
License Agreement in the fields of both antiviral and anticancer research.

Biokeys Pharmaceuticals, Inc. is a biopharmaceutical research and development company whose business strategy is to
commercialize leading edge medical research through licensing agreements with prominent universities and research
institutions. The Company focuses its energy in cancer and antiviral research to launch products that either extend the
usefulness of current therapies or replace marginal therapies with new approaches to treatment. The Company's lead
compound, CoFactor(TM), is a chemotherapy biomodulator designed to be used in conjunction with 5-FU, the world's most
frequently used cancer drug. CoFactor is being readied to enter Phase II/III human clinical trials in the U.S. and Europe. Also
in development is EradicAide(TM), a cell mediated, antibody-negative immunotherapeutic/vaccine for HIV Infection/AIDS. In
recently completed primate trials EradicAide has shown the ability to reduce HIV viral loads to undetectable levels with no
development of viral disease or resistance.

This press release contains forward-looking statements within the meaning of the ``safe harbor'' provisions of the Private
Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and
beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties
inherent in the drug development process, the timing and success of clinical trials, and the receipt of necessary approvals
from the United States Food and Drug Administration. The Company undertakes no obligation to release publicly any
revisions, which may be made to reflect events or circumstances after the date hereof.
 

13.06.01 12:22

549 Postings, 7423 Tage DonHappyweitere wichtige info für potentielle investoren

Zwischenbericht zur aktuellen Situation von Biokeys Inc.
1. Krebsmedikament CoFactor
Nach Abschluß der klinischen Prüfung Phase I/II in Schweden, strebt Biokeys Inc. jetzt Phase II
Prüfungen in Schweden und in den USA an. In der abgeschlossen Untersuchung wurden 62
Patienten mit unterschiedlichen Tumorerkrankungen behandelt, bei denen vorhergehende
Therapien mit anderen Wirkstoffkombinationen erfolglos waren. CoFactor verstärkt die Effizienz
des weltweit häufig eingesetzten Krebsmedikaments 5-Fluoruracil (5-FU). In dieser Funktion kann
es das bisher verwendete Medikament Leucovorin, das ebenfalls die Wirkung von 5-FU verstärkt,
ersetzen. In klinischen Studien wird CoFactor mit der Wirkung von Leucovorin verglichen. In der
schwedischen Studie verhalf die Kombination 5-FU mit CoFactor den Patienten im Mittel zu 9 -15
Monaten in denen die Krankheit nicht fortschritt, was eine deutliche Verbesserung gegenüber der
Therapie mit 5-FU/Leucovorin darstellt. Die untersuchte Kombination 5-FU/CoFactor rief weniger
unerwünschte Nebenwirkungen hervor, als bei Therapien mit 5-FU oder 5-FU/Leucovorin. Dieser
Punkt ist besonders positiv für die angestrebte Zulassung von CoFactor. CoFactor per se zeigte
gar keine Toxizität. Bei 21 % bis 55 % der Patienten (die Prozentzahlen unterscheiden sich nach
der Grunderkrankung: Darm-, Brust-, Bauchspeicheldrüsen-, Gallenblasen- und Magen-Krebs)
sprachen die Tumoren auf die Behandlung an.
 

   Antwort einfügen - nach oben